The reactivation of resolved hepatitis B virus (HBV) infection is termed reverse seroconversion (RS). HBV-RS is a complication after allogeneic stem cell transplantation (SCT) in patients exposed to hepatitis B virus [1] [2] [3] [4] . Recently, Onozawa et al [1] reported that HBV vaccination is effective in the prevention of HBV-RS after SCT, but there are limited data about RS of hepatitis B in long-term SCT survivors. At our institute, 15 of 103 patients with hematologic disorders (14 leukemia or myelodysplastic syndrome [MDS] , 1 severe apalstic anemia [AA] ) receiving SCT from an HLA identical sibling and surviving 3 or more years, had a pretransplant resolved HBV infection (negative HBsAg, positive anti-HBs and anti-HBc antibodies). Twelve (median age 39.5 years) had received total body irradiation (TBI)-based myeloablative SCT followed by a T cell-depleted peripheral blood stem cell transplantation (PBSCT), and 3 (median age 13 years) received a reduced-intensity regimen (RIC) of fludarabine (Flu) and cyclophosphamide (Cy), followed by PBSCT. All received cyclosporine (CsA) as graft-versus-host disease (GVHD) prophylaxis. Eight developed acute GVHD (aGVHD), and 12 developed chronic GVHD (cGVHD), 8 of whom continued immunosuppressive therapy (IST) 3 years or more after SCT. Serologic HBV markers were followed serially (median follow-up 59 months; range: 40-113).
The probability of developing HBV-RS posttransplant in recipients with resolved pretransplant HBV infection was 30%. Five patients, 3 of whom had received lamivudine, developed RS with reappearance of HBsAg, 21-101 (median 31) months after SCT. Three developed clinical hepatitis, which was successfully treated with lamivudine with a decrease of HBV viral load after additional antiviral drugs in one. Of the 10 patients who did not have RS, 6 were vaccinated with HBV around 1 year posttransplant and 5 also received lamivudine prophylaxis starting 3 months posttransplant and continuing until anti-HBs antibody became positive. The median length of lamivudine prophylaxis time was 16.6 months. Six donors had been vaccinated for HBV or had resolved HBV infection pretransplant. Two recipients of these donors developed RS (Table 1 ). Fourteen (93%) patients are alive (median follow-up 59 months). One patient with RS died with relapsed myodysplastic syndrome (MDS), 59 months after SCT. There was no significant difference in the age, conditioning regimen, incidence of aGVHD or cGVHD, nor duration of IST between RS and non-RS patients.
The frequency of RS in our series was within the range of 14%-50% reported [1] [2] [3] 5] . However the median time to RS was longer (29 months versus 19 months; range: 6-72 months) [2, 4] . Variations may be attributable to different immunosuppressive regimens or different incidence and severity of cGVHD. The presence of cGVHD may result in earlier onset of RS [3, 6] , but this was not a significant factor in our small series. These results emphasize the need for continued monitoring for HBV RS in patients at risk, especially those receiving prolonged IST [2] . Prophylactic vaccination with hepatitis B vaccine for patients with pretransplant resolved HBV infection is recommended beginning 1 year posttransplant or after withdrawal of IST [1] , and hepatitis B vaccination of the donor may help to prevent RS by passive transfer of immunity against HBV to the SCT recipients [7] , although neither prior HBV infection nor vaccination is completely protective as we also found [6] . Therefore, the recipient should also receive early posttransplant vaccination following donor Hepatitis B vaccination. Although lamivudine prophylaxis can prevent RS of HBV, it is unknown at what stage prophylaxis can be discontinued [8] and fatal fulminant hepatitis B has occurred after withdrawal of lamivudine in SCT patients [8] .
Since 2004, our policy for patients with positive anti-HBc antibody before SCT, is to give lamivudine 100 mg/day, within 3 months posttransplant, vaccinate around 1 year post-SCT, and continue lamivudine until the anti-HBs antibody becomes positive. HBV reactivation is monitored at regular intervals by testing HBsAg, HBV-DNA, anti-HBs, and anti-HBc antibodies. Antiviral therapy, for example, lamivudine therapy, should be considered early in patients positive for HBV-DNA; additionally, newer anti-HBV agents like adefovir, entecavir, telbivudine, and tenofovir, could be used if lamivudine resistance occurs.
In conclusion, RS of HBV post-SCT is a significant long-term complication in patients with pretransplant-resolved HBV infection. Our study emphasizes the importance of posttransplant prophylaxis with lamivudine, hepatitis B vaccine, long-term hepatitis B serologic monitoring, and prompt initiation of lamivudine treatment if HBV-RS occurs. Acute graft-versus-host disease (aGVHD) causes serious morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Outcomes of therapy with glucocorticoids may be suboptimal, and patients who do not respond to steroids have a poor prognosis. The pathogenesis of aGVHD involves a cytokine storm induced by pretransplantation conditioning along with dendritic cell and T cell activation, leading to up-regulation of inflammatory cytokines and alloreactive donor lymphocytes that attack recipient tissues [1] . Interleukin (IL)-2 is a T cell-derived cytokine that plays a central role in immune responses by inducing activated T cell proliferation, facilitating B cell activation and proliferation, and modulating macrophage function.
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Denileukin diftitox (Ontak; Eisai Medical Research, Seragen, Inc, Hopkinton, MA, License #1258) is a recombinant fusion protein that preferentially binds with high affinity to T cells expressing IL-2 receptors (CD25) [2] . Some previous reports have indicated that denileukin diftitox depletes the CD4 1 /CD25 high subset of T regulatory (Treg) cells, a mechanism that has been implicated in the drug's activity against tumors [3] . The same subset of Treg cells suppresses alloreactive T cells and is an important regulator of the GVHD response [4] . It has been hypothesized that selective binding and depletion of activated T cells 
